Oral Fluid Collection for Molecular Testing

About OraSure Technologies

OraSure Technologies' mission is to empower individuals and healthcare providers with rapid, accurate, and accessible diagnostic information. The company has achieved market leadership in oral fluid diagnostics, most notably with its FDA-approved OraQuick® tests for HIV and HCV, and its InteliSwab® COVID-19 test. Its strategy focuses on expanding its rapid test portfolio, growing its molecular collection business, and leveraging its platforms into new disease areas and geographic markets to drive sustainable growth beyond pandemic-related revenue.

Therapeutic Areas